Welcome to our dedicated page for Camp4 Therapeutics news (Ticker: CAMP), a resource for investors and traders seeking the latest updates and insights on Camp4 Therapeutics stock.
CAMP4 Therapeutics Corporation (Nasdaq: CAMP) is a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics designed to upregulate gene expression and restore healthy protein levels in genetic diseases. The CAMP news feed highlights how the company advances its antisense oligonucleotide (ASO) pipeline, progresses clinical and preclinical programs, and enters strategic collaborations.
Readers can follow CAMP4’s updates on its SYNGAP1-related disorders program, including announcements about GLP toxicology studies for CMP-SYNGAP-01, translational data in humanized mouse models and non-human primates, and plans for Phase 1/2 clinical trial applications. News items also cover the company’s Urea Cycle Disorders program and the CMP-CPS-001 (CMP-001) Phase 1 trial, where CAMP4 has reported safety and pharmacokinetics data from single and multiple ascending dose cohorts in healthy volunteers.
CAMP4’s news flow includes financial and corporate updates such as private placements, underwritten offerings of common stock, and use of proceeds to support development of its product candidates. The company also reports on strategic agreements, including a research, collaboration and license agreement with GSK to discover and develop ASO drug candidates for neurodegenerative and kidney disease indications using CAMP4’s RAP Platform.
In addition, CAMP4 issues press releases on scientific presentations at major meetings, corporate highlights, and inducement grants under Nasdaq Listing Rule 5635(c)(4). Investors and observers can use this news page to review CAMP4’s reported milestones, research progress, and financing activities related to its regulatory RNA-targeting therapeutic strategy.
CAMP4 (Nasdaq: CAMP) will participate in three investor conferences in March and April 2026, presenting company updates and hosting a fireside chat and corporate presentations.
Events include Leerink Global Healthcare (March 9, 2026, fireside chat, Miami), Stifel CNS Forum (March 17, 2026, virtual) and Needham Healthcare (April 13, 2026, virtual). Live webcasts and 30-day replays will be available on CAMP4's investor relations site.
CAMP4 (Nasdaq: CAMP) reported full-year 2025 results and corporate highlights on March 5, 2026, emphasizing progress on its SYNGAP1 program and a strategic collaboration with GSK.
Key points: GLP toxicology for CMP-002 ongoing; global Phase 1/2 in SYNGAP1 patients targeted as early as H2 2026; $17.5M upfront from GSK plus up to $440M in milestones and tiered royalties; financing raised including $50M upfront private placement and $30M underwritten offering; cash of $109.5M expected to fund operations into 2028; 2025 net loss $80.4M.
CAMP4 Therapeutics (Nasdaq: CAMP) announced an inducement option grant on February 16, 2026 to a newly hired employee. The company granted a non-qualified stock option for 8,000 shares with a 10-year term and an exercise price of $3.85, equal to the closing price on the grant date.
The option vests over four years: 25% on the first anniversary and the remainder in 36 equal monthly installments, subject to continued service, under an Inducement Option Award Agreement.
CAMP4 Therapeutics (Nasdaq: CAMP) announced an inducement equity award granted on January 15, 2026 under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee granted a non-qualified stock option for 8,000 shares to a newly hired employee with a 10-year term and an exercise price of $5.78 per share (closing price on the grant date). The option vests over four years: 25% at the one-year anniversary, then monthly over 36 months, subject to continued service, and is governed by an Inducement Option Award Agreement.
CAMP4 (Nasdaq: CAMP) announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 3:45 p.m. PST.
The presentation will be webcast and accessible via CAMP4's investor relations website at www.investors.camp4tx.com. A replay will be archived on the CAMP4 website for 30 days following the conference.
CAMP4 Therapeutics (Nasdaq: CAMP) priced an underwritten offering of 5,000,000 common shares at $6.00 per share, for gross proceeds of $30.0 million. The offering is expected to close on or about December 19, 2025, subject to customary closing conditions.
The company said net proceeds, together with existing cash and marketable securities, will be used to support continued development activities for its product candidates and for general corporate purposes. Leerink Partners is sole underwriter; participants include Janus Henderson Investors, Coastlands Capital, EcoR1 Capital, Trails Edge Capital Partners, Vivo Capital and a large mutual fund complex. A Form S-3 registration became effective on December 1, 2025.
CAMP4 (Nasdaq: CAMP) entered a strategic research, collaboration and license agreement with GSK on Dec 18, 2025 to apply CAMP4’s RAP Platform® to identify antisense oligonucleotide (ASO) candidates for neurodegenerative and kidney diseases.
Under the deal CAMP4 will receive $17.5 million upfront, is eligible for additional milestone payments and tiered royalties, and will deliver discovery-stage regRNA-targeting ASOs while GSK will lead development and commercialization.
CAMP4 Therapeutics (Nasdaq: CAMP) announced on December 11, 2025 that its Board approved inducement grants under Nasdaq Listing Rule 5635(c)(4).
The Board granted non-qualified stock options to purchase an aggregate of 92,000 shares to four newly hired employees. Each option has a ten-year term and an exercise price of $6.01, equal to CAMP4’s closing share price on the grant date.
The options vest over four years with 25% vesting at the one-year anniversary and the remainder vesting in 36 equal monthly installments, subject to continued service and the terms of an Inducement Option Award Agreement.
CAMP4 Therapeutics (Nasdaq: CAMP) announced an inducement stock option grant on November 12, 2025 to a newly hired employee under Nasdaq Listing Rule 5635(c)(4).
The Board granted a non‑qualified option to purchase 80,000 shares with a 10‑year term and an exercise price of $4.39, equal to the closing price on the grant date. The option vests over four years: 25% after one year, then the remainder in 36 monthly installments, subject to continued service, and is governed by an Inducement Option Award Agreement.
CAMP (Nasdaq: CAMP) reported Q3 2025 results and corporate updates on Nov 6, 2025. Key items include a private placement initial closing of $50M (up to $100M total) that management says extends runway into 2027, and cash and marketable securities of $75.3M as of Sept 30, 2025 (up from $39.1M on June 30, 2025).
Clinical progress: initiated GLP toxicology studies for CMP-002 to support a planned Phase 1/2 filing with potential trial start as early as H2 2026; completed MAD analysis for CMP-001 showing favorable safety and PK and received a Netherlands CTA to start a Phase 1b in OTC heterozygotes. Q3 operating items: R&D $9.4M, G&A $4.6M, net loss $15.1M.